Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
2027. febr. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
DK222 Study at Hopkins
2027. jan. 31.· PHASE1 · RECRUITING· CTGOV
Vizsgálat
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
2026. dec. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
2026. nov. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2026. nov. 30.· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
2026. nov. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
2026. nov. 15.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
2026. nov. 11.· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publikáció
[PD-L1 expression in brain metastatic lung adenocarcinoma: correlation of clinicopathological features with prognosis].
2026. nov. 8.· Zhonghua bing li xue za zhi = Chinese journal of pathology· PUBMED
Publikáció
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC.
2026. nov. 6.· Future oncology (London, England)· PUBMED
Publikáció
RIG-I is essential for radiation-induced IFN-β production and PD-L1/PD-L2 upregulation in HPV-negative head and neck squamous cell carcinoma cells.
2026. nov. 6.· Oncoimmunology· PUBMED
Publikáció
CircRNA9389 inhibits NKRF nuclear translocation to activate the NFκB pathway and upregulate PD-L1 expression promoting colorectal cancer progression.
2026. nov. 5.· International journal of biological macromolecules· PUBMED
Publikáció
HB0025, a Novel Anti-PD-L1/VEGF Trap Bispecific Antibody Plus Chemotherapy in Advanced Non-Small Cell Lung Cancer.
2026. nov. 5.· JAMA oncology· PUBMED
Publikáció
PD-1/PD-L1 inhibitors plus chemotherapy in cervical cancer: A systematic review and meta-analysis.
2026. nov. 5.· Turkish journal of obstetrics and gynecology· PUBMED
Publikáció
Beyond CD4⁺/CD8⁺: NK-Cell PD-L1 Expression and Adaptive Immune Checkpoint Profiles in People with HIV.
2026. nov. 5.· Immunology letters· PUBMED
Publikáció
Targeting CLDN3 Enhances PD-1 Blockade Efficacy in Gastric Cancer by Disrupting the NF-κB/p65-CXCL1-PD-L1 Immune Evasion Axis.
2026. nov. 4.· The Journal of biological chemistry· PUBMED
Publikáció
Targeting ERO1A Enhances Antitumor Immune Response by Recruiting CD8+ T Cells and Synergizing with PD-L1 Blockade in Liver Cancer.
2026. nov. 3.· Cancer immunology research· PUBMED
Publikáció
Dynamic contrast-enhanced MRI and tumor microenvironment in hepatocellular carcinoma: exploratory analysis of CD3 + TILs, PD-L1, and glypican-3.
2026. nov. 3.· European radiology experimental· PUBMED
Publikáció
Prognostic value of PD-L1 expression and association with HRD in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1/ENGOT-ov25 trial (GINECO).
2026. nov. 3.· ESMO open· PUBMED
Publikáció
Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients.
2026. nov. 2.· The Journal of clinical investigation· PUBMED
Publikáció
BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer.
2026. nov. 2.· Molecular pharmaceutics· PUBMED
Vizsgálat
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
2026. nov. 1.· PHASE2 · WITHDRAWN· CTGOV
Vizsgálat
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
2026. nov. 1.· NA · RECRUITING· CTGOV
Vizsgálat
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
2026. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Integration of TRM-Cell Infiltration and PD-L1 Expression Improves Prognostic Stratification After Resection of NSCLC.
2026. nov. 1.· Anticancer research· PUBMED
Publikáció
c-MET Inhibition Is Accompanied by PD-L1 Upregulation and Immunosuppression-Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti-PD-1 Therapy.
2026. nov. 1.· Cancer medicine· PUBMED